Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer


Autoria(s): Reis, Sabrina Thalita; Leite, Katia Ramos M.; Piovesan, Luis Felipe; Pontes-Junior, Jose; Viana, Nayara Izabel; Abe, Daniel Kanda; Crippa, Alexandre; Moura, Caio Martins; Adonias, Sanarelly Pires; Srougi, Miguel; Dall'Oglio, Marcos Francisco
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

04/11/2013

04/11/2013

02/08/2013

Resumo

Background: Extracellular matrix homeostasis is strictly maintained by a coordinated balance between the expression of metalloproteinases (MMPs) and their inhibitors. The purpose of this study was to investigate whether the expression of MMP-9, MMP-2 and its specific inhibitors, are expressed in a reproducible, specific pattern and if the profiles are related to prognosis in Bladder Cancer (BC). Methods: MMP-9, MMP-2 and its specific inhibitors expression levels were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) in fresh-frozen malignant tissue collected from 40 patients with BC submitted to transurethral resection of bladder. The control group consisted of normal bladder tissue from five patients who had undergone retropubic prostatectomy to treat benign prostatic hyperplasia. Results: MMP-9 was overexpressed in 59.0 % of patients, and MMP-2, TIMP-1, TIMP-2, MMP-14, RECK and IL-8 was underexpressed in most of the patients. Regarding prognostic parameters we observed that high-grade tumors exhibited significantly higher levels of MMP-9 and IL-8 (p = 0.012, p = 0.003). Invasive tumors (pT1-pT2) had higher expression levels of MMP-9 than superficial tumors (pTa) (p = 0.026). The same was noted for IL-8 that was more expressed by invasive tumors (p = 0.015, p = 0.048). Most importantly tumor recurrence was related with higher levels of both MMP-9 (p = 0.003) and IL-8 (p = 0.005). Conclusion: We have demonstrated that the overexpression of MMP-9 and higher expression of IL-8 are related to unfavorable prognostic factors of urothelial bladder cancer and tumor recurrence and may be useful in the follow up of the patients.

FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [2009/50368-9]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Identificador

BMC UROLOGY, LONDON, v. 12, n. 1, supl. 1, Part 3, pp. E1-E3, 41426, 2012

1471-2490

http://www.producao.usp.br/handle/BDPI/37996

10.1186/1471-2490-12-18

http://dx.doi.org/10.1186/1471-2490-12-18

Idioma(s)

eng

Publicador

BIOMED CENTRAL LTD

LONDON

Relação

BMC UROLOGY

Direitos

openAccess

Copyright BIOMED CENTRAL LTD

Palavras-Chave #BLADDER CANCER #MATRIX METALLOPROTEINASE #PROGNOSIS #DIAGNOSIS #GENE EXPRESSION #METASTASIS SUPPRESSOR RECK #MATRIX METALLOPROTEINASES #DOWN-REGULATION #COLORECTAL-CANCER #TISSUE INHIBITORS #CELL-CARCINOMA #TUMOR-GROWTH #INVASION #GENE #MATRIX-METALLOPROTEINASE-9 #UROLOGY & NEPHROLOGY
Tipo

article

original article

publishedVersion